Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis.
We have previously shown that deficiency in the anti-inflammatory cytokine interleukin-10 (IL-10) is responsible for enhanced angiogenesis after hindlimb ischemia. This study examined the putative involvement of matrix metalloproteinase (MMP) activation in this process. Ischemia was produced by artery femoral occlusion in both C57BL6 IL-10(+/+) and IL-10(-/-) mice. Angiographic vessel density and laser Doppler perfusion data at day 28 showed significant improvement in ischemic/nonischemic leg ratio by, respectively, 1.8-fold and 1.4-fold in IL-10(-/-) mice compared with IL-10(+/+) mice. This was associated with an increase in vascular endothelial growth factor (VEGF) protein content in the ischemic hindlimb. Three days after ischemia, gelatin zymography showed a significant increase in both pro- and active forms of MMP-2 and MMP-9 in ischemic hindlimbs of IL-10(-/-) mice compared with IL-10(+/+) mice (P<0.01). This increase in MMP activity in IL-10(-/-) mice was completely inhibited by treatment with BB-94 (5 mg/kg IP), a specific MMP inhibitor. Furthermore, increases in both vessel density and blood perfusion indexes at day 28 in IL-10(-/-) mice were abolished after treatment with BB-94 (0.78+/-0.06 versus 1.17+/-0.09 and 0.62+/-0.02 versus 0.88+/-0.04, for vessel density and blood perfusion ratio, respectively, in IL-10(-/-) mice treated with BB-94 versus untreated IL-10(-/-) mice, P<0.05). In contrast, BB-94 treatment did not affect the rise in VEGF protein content. These findings in IL-10(-/-) mice underscore the critical role of MMP activation, in a context of increased VEGF expression, in promoting ischemia-induced angiogenesis.
Silvestre
J S
JS
Institut National de la Santé et de la Recherche Médicale U541, Hôpital Lariboisière, Institut Federatif de Recherche Circulation-Lariboisière, Université Paris, France.
Mallat
Z
Z
Tamarat
R
R
Duriez
M
M
Tedgui
A
A
Levy
B I
BI
D000792:Angiography; D000818:Animals; D001783:Blood Flow Velocity; D002196:Capillaries / Q000166:cytology / Q000378:metabolism; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006614:Hindlimb / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology; D016753:Interleukin-10 / Q000172:deficiency / Q000378:metabolism* / Q000494:pharmacology; D007511:Ischemia / Q000150:complications / Q000503:physiopathology*; D017078:Laser-Doppler Flowmetry; D008222:Lymphokines / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000096:biosynthesis; D011480:Protease Inhibitors / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D061965:Matrix Metalloproteinase Inhibitors; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011480:Protease Inhibitors; D013876:Thiophenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D016753:Interleukin-10; D010649:Phenylalanine; C080985:batimastat; D020782:Matrix Metalloproteinases